Zevra Therapeutics, Inc.
ZVRA
$9.98
-$0.21-2.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2,336.21% | -100.73% | 2,510.68% | 91.33% | -7.57% |
| Total Depreciation and Amortization | -7.65% | -76.26% | 0.12% | 0.06% | 1.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -57.71% | 109.89% | -101,030.56% | -99.69% | 69.31% |
| Change in Net Operating Assets | -331.74% | 68.06% | -6.50% | -27.57% | -2,144.77% |
| Cash from Operations | 17.14% | 230.77% | 56.20% | 49.40% | 10.42% |
| Capital Expenditure | 105.60% | -160.09% | -115.15% | -- | -- |
| Sale of Property, Plant, and Equipment | -123.94% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 107.31% | -137.96% | 14.15% | 294.50% | 82.55% |
| Cash from Investing | 104.96% | -138.34% | 13.20% | 292.69% | 82.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -61.01% | 372.85% | -30.22% | 148.62% | -98.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -61.01% | 372.85% | -14.06% | 101.88% | -98.77% |
| Foreign Exchange rate Adjustments | -603.13% | -90.27% | 276.88% | -155.44% | 236.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.43% | -35.14% | 191.76% | 117.55% | -237.05% |